Feng Ye

机构：Pfizer (United States), South China Normal University, Chinese Academy of Medical Sciences & Peking Union Medical College, First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Xi'an Jiaotong University, State Key Laboratory of Respiratory Disease, Children's Hospital of Chongqing Medical University, First Affiliated Hospital Zhejiang University, Guangzhou Institute of Respiratory Health, Zhejiang University, Chongqing Medical University, Guangzhou Medical University · ORCID：0000-0003-1418-7980

发表论文 155 篇 · 总被引 4992 次 · h-index 29

代表论文

• Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021 (2024 · JHEP Reports · 被引 116)
• Polymyxin B-targeted liposomal photosensitizer cures MDR A. baumannii burn infections and accelerates wound healing via M1/M2 macrophage polarization (2024 · Journal of Controlled Release · 被引 53)
• Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (2024 · The Lancet Infectious Diseases · 被引 36)
• A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease (2024 · Hepatology International · 被引 34)
• acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study (2024 · Clinical Gastroenterology and Hepatology · 被引 17)
• Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study (2024 · Vaccine · 被引 15)